# PDR001 Plus Imatinib for Metastatic or Unresectable GIST

> **NCT03609424** · PHASE1,PHASE2 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 39 (actual)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** PDR001, Imatinib

## Key facts

- **NCT ID:** NCT03609424
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-14
- **Primary completion:** 2021-11-11
- **Final completion:** 2021-11-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2023-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03609424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03609424, "PDR001 Plus Imatinib for Metastatic or Unresectable GIST". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03609424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*